Induced Pluripotent Stem Cell Therapy Company Century Therapeutics Raises $250 Million

By Dan Anderson ● July 8, 2019
  • Century Therapeutics — a company that was created by Versant Ventures — recently emerged from stealth and raised $250 million

Century Therapeutics — a company that was created by Versant Ventures as part of the company’s core strategy to launch innovative biotech companies — recently emerged from stealth mode with $250 million in financing commitments from Bayer, Versant and Fujifilm Cellular Dynamics Inc. (FCDI). This round of funding will enable Century to advance multiple programs into the clinic for hematologic and solid malignancies.

ADVERTISEMENT

This funding round establishes Leaps by Bayer as an integral partner in Century’s investor syndicate. Leaps by Bayer — which is a venture investment arm of the global life sciences company Bayer — is dedicated to making paradigm-shifting advances in the life sciences. And Leaps by Bayer is heavily focused on curing and preventing cancer since the disease still represents one of today’s biggest health concerns with limited curative or preventative therapies available.

ADVERTISEMENT

“We are very excited about the potential of Century’s platform. It represents a unique opportunity in the development of next-generation cell therapies that promise to address previously incurable cancers,” said the head of Leaps by Bayer Dr. Jürg Eckhardt.

Century was launched by Versant in 2018 and later that year formed a strategic partnership with FCDI — which is a subsidiary of Fujifilm Corporation — to develop iPSC-derived immune effector cells for cancer. FCDI’s vertically integrated iPSC platform has been optimized over the past 15 years to include the foremost reprograming technology that uses genome integration-free methods to generate GMP grade iPSC lines.

And Century has exclusive access to FCDI’s leading immune effector cell differentiation protocols and intellectual property to manufacture GMP-grade immune effector cells at commercial scale. Through the terms of the iPSC platform license agreement, FCDI will serve as the primary manufacturer of Century’s cellular products.

ADVERTISEMENT

“Versant believes that allogeneic reagents represent the next wave of innovation in cell therapy and created Century to engineer truly off-the-shelf products to treat both hematologic and solid tumors,” added Carlo Rizzuto, Ph.D. — a Versant partner and Century director. “Today’s financing marks an important milestone in our effort to enable cell therapies to treat a much broader array of cancer patients.”

Century was founded by Marcela Maus, MD, Ph.D., assistant professor of medicine at Harvard Medical School and director of the Cellular Immunotherapy Cancer Center at Massachusetts General Hospital, and Hiromitsu Nakauchi Hiro, MD, Ph.D., professor of genetics at Stanford University School of Medicine.

ADVERTISEMENT

“Fujifilm’s mission is to bring new value to society through innovation and the creation of new technologies, products and services. We are confident that FCDI’s cutting edge iPSC technologies and promising regenerative medicine solutions currently under development, can create new value to fulfill unmet medical needs and improve the lives of patients around the world,” explained Toshikazu Ban —  Corporate Vice President of Fujifilm Corporation. “By accelerating development of new cancer immunotherapies using allogeneic iPSC through Century, we aim to deliver the therapy to patients as soon as possible.”

Century’s foundational technology is built on induced pluripotent stem cells (iPSCs) — which have an unlimited self-renewing capacity. This enables multiple rounds of cellular engineering to produce master cell banks of modified cells that can be expanded and differentiated into immune effector cells for supplying vast amounts of allogeneic and homogeneous therapeutic products. The platform differentiates Century from competitors that are developing cell therapies made from non-renewable donor-derived cells.

“The financial support and expertise from this consortium of partners will enable Century to realize the full potential of our iPSC platform and expand patient access to cell therapy,” noted Lalo Flores, Ph.D. — CEO of Century. “I am grateful to have their experience to guide the development of our promising allogeneic cell therapies for cancers with high unmet need.”

Along with bringing on Dr. Flores, Century attracted a highly experienced team in cell therapy research and development that includes Hyam Levitsky, MD, President of Research and Development; Luis Borges, PhD., Chief Scientific Officer; and Adrienne Farid, PhD., Chief Development Officer.